The Journal of Practical Medicine ›› 2020, Vol. 36 ›› Issue (21): 3013-3017.doi: 10.3969/j.issn.1006⁃5725.2020.21.026

• Reviews • Previous Articles     Next Articles

Progress in clinical treatment of Kaposi sarcoma

LU Feiyan,ZENG Yi,ZHAO Lijuan   

  1. Department of Pathogenic Microbiology and Immunology of Youjiang Medical University for Nationalities,Baise 533000,China
  • Online:2020-11-10 Published:2020-11-30
  • Contact: ZHAO Lijuan E⁃mail:zhaolijuanxk@163.com

Abstract:

Kaposi′s sarcoma(KS)is an aggressive lymphoangioproliferative tumor. Its occurrence is closelyrelated to the infection of endothelial cells by Kaposi sarcoma associated herpesvirus (KSHV). KS caused byKSHV is a common concurrent malignant tumor of AIDS,which is more common in Mediterranean and Africa,with high mortality. The treatment of Kaposi sarcoma is one of the difficult problems in clinical practice. In recentyears,KS has achieved a breakthrough. Especially after the advent of CART ,the incidence rate of KS hasdecreased significantly,and the prognosis of patients has improved significantly. This article reviews the progress ofclinical treatment of Kaposi′s sarcoma.

Key words: Kaposi sarcoma, KSHV, Kaposi sarcoma treatment, CART